Salazopyridazine
目录号 : GC68208Salazopyridazine 是一种抗菌剂。Salazopyridazine 对溃疡性结肠炎有抑制作用。Salazopyridazine 可用于风湿病的研究。
Cas No.:22933-72-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Salazopyridazine is an antibacterial agent. Salazopyridazine shows activities against ulcerative colitis. Salazopyridazine can be used for the research of rheumatic diseases[1][2].
[1]. Sigidin IaA. Institut Revmatizma RAMN i progress antirevmatichesko? terapii [Institute of Rheumatology and progress of antirheumatic therapy]. Vestn Ross Akad Med Nauk. 1998;(12):7-9.
[2]. Belohlavek D, et al. EntzÜndliche Darmerkrankungen Colitis ulcerose und M. Crohn. FrÜhdiagnose und Behandlung [Inflammatory intestinal diseases: ulcerative colitis and Crohn's disease. Early diagnosis and treatment]. Fortschr Med. 1976 Mar 4;94(7):358-62.
| Cas No. | 22933-72-8 | SDF | Download SDF |
| 分子式 | C18H15N5O6S | 分子量 | 429.41 |
| 溶解度 | DMSO : 125 mg/mL (291.10 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3288 mL | 11.6439 mL | 23.2878 mL |
| 5 mM | 0.4658 mL | 2.3288 mL | 4.6576 mL |
| 10 mM | 0.2329 mL | 1.1644 mL | 2.3288 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Institute of Rheumatology and progress of antirheumatic therapy]
Vestn Ross Akad Med Nauk 1998;(12):7-9.PMID:9987950doi
The paper deals with the achievements of the Institute of Rheumatology in antirheumatic therapy, among them there are methods of objective assessment of antirheumatic drugs, the first use of antimalarials in the treatment of chronic rheumatic fever, discovery of immunodepressive properties of these drugs, specification of the mechanism of action of several NSAIDs. Antilymphocytic globulin, Salazopyridazine and the alkylating drug dopan were used for the first time in therapy of rheumatic diseases. Administration of the most potent NSAIDs diclofenac or indomethacin to patients with acute rheumatic fever proved to be as effective as prednizolone. Special attention is paid to the combination treatment of rheumatoid arthritis with NSAIDs. The concurrent administration of aurannofin and methotrexate was shown to cause a more rapid development of clinical improvement than monotherapy with either drug. A combination of gold aurothiomalate and hydroxychloroquine and that of low doses of D-penicillamine and cyclophosphamide had no advantages over monotherapy. Revealing the therapeutical potential of antibodies to interferon-gamma in the treatment of rheumatic arthritis and psoriatic arthritis was the most important achievement of recent years. These studies open new vistas for anticytokine treatment of rheumatic diseases.
[The comparative efficacy of slow-acting (basic) preparations in psoriatic arthritis]
Ter Arkh 1992;64(5):54-9.PMID:1360714doi
Overall 126 patients with verified and clinically active psoriatic arthritis (PA) were subjected to a randomized study of the efficacy of chrisanolum (Chr), sulfasalicylic drugs (SSD) (sulfasalazine and Salazopyridazine) and methotrexate (MT) as compared to nonsteroidal anti-inflammatory drugs (NSAID). The treatment that lasted for a year was completed by 77 patients: in the group on NSAID, by 31, on Chr by 15, on SSD by 15, and on MT by 16. In the remainder, the treatment was discontinued because of side effects. The best clinical effect was recorded in patients on Chr. The improvement was observed in 73% of the patients, with a significant effect being attained in 60%. In the groups on SSD and MT, the improvement was observed in 80 and 69%, respectively. However, noticeable improvement was only recorded in 20 and 19%. SSD turned out more effective than MT. in the group on NAID, the improvement was ascertained but in 35% of the patients, with noticeable one being attained in 6%. According to Pearson's criterion chi 2, the results of the treatment with NAID alone were less potent than in the group given Chr (p < 0.001) and SSD (p < 0.05). The differences between the effect of the treatment with NAID and MT appeared nonsignificant (p > 0.1). Therefore, according to the diminution of the clinical efficacy in PA, the basic drugs may be distributed in the following way: Chr, SSD, MT. The side-effects in the group on NAID were. recorded in 37% of cases, in the group on Chr in 53%, on SSD in 33%, and on MT in 55%. This means that SSD were tolerated best of all.
[The cytochemical characteristics of neutrophilic leukocytes in the peripheral blood and synovial fluid of patients with rheumatoid arthritis in the course of treatment]
Revmatologiia (Mosk) 1990 Oct-Dec;(4):22-9.PMID:1981626doi
The authors studied the activity of alkaline and acid phosphatase (AP), myeloperoxidase (MP), the level of cationic protein (CP), spontaneous and pyrogenal-induced tests of restoration of nitroblue of tetrazolium (HCT-test) in the blood and synovial fluid (SF) neutrophils in 116 patients with rheumatoid arthritis (RA) in the dynamics of a 3-4-week and subsequent 6-month therapy with chrysanol, Salazopyridazine and delagil. In the active phase all the patients exhibited an abrupt increase in the activity of alkaline and acid phosphatase in blood neutrophils, a drop in the level of CP (in 69%), a rise in the activity of MP (in 32%); pyrogenal did not induce any capacity for restoring HCT (in 44%). Indices of alkaline and acid phosphatase in blood and SF neutrophils and also of the induced TCT-test in blood neutrophils correlated with the degree of RA activity. Statistically significant positive cytochemical shifts were noted only after 6 months of treatment: a decrease in alkaline and acid phosphatase activity, a rise in the level of CP, MP and capacity for restoration pf HCT with pyrogenal in blood neutrophils. Increase in the correlation of CP or MP levels by 0.2 or more in blood and SF neutrophils, and also of the normal level of CP in blood neutrophils or its increase not less than by 15% 3-4 weeks after the beginning of therapy evidence good prognostic informativeness with respect to the effectiveness of basic therapy.
[The effect of basic therapy on the morphological picture of the rectal mucosa in patients with rheumatoid arthritis]
Ter Arkh 1995;67(11):76-80.PMID:8571264doi
140 rectal mucosa biopsies were obtained from 86 patients with rheumatoid arthritis (RA), from 54 RA patients prior to or after a year basic therapy with either methotrexate or sulfa drug (sulfasalazine or Salazopyridazine). 80% of the examinees exhibited large macrophages, lymphoid follicules, IgM- and IgG-containing cells. The knowledge of the initial morphologic changes in the rectal mucosa from RA patients helps predict efficacy of methotrexate or sulfonic drug treatment. Rectoromanoscopy with biopsy proved important diagnostic tool in RA capable of differentiating the disease variants, prompting valid therapeutic approach with control of the treatment results.
[The efficacy of bifidum-containing preparations in enterogenous reactive arthritis]
Ter Arkh 1991;63(5):33-6.PMID:1887411doi
Analysis is made of the intestinal microflora in 43 patients suffering from reactive arthritides (ReA) that developed after intestinal infection. The overwhelming majority of the patients manifested a decrease of the level of the bifidoflora. The disorders of the intestinal microflora were related to the disease activity and standing. Bifidumbacterine was found to produce a significant beneficial effect on the course of ReA and to cause no serious side effects. According to the preliminary data, the efficacy of bifidumbacterin exceeded that of the known basic drug Salazopyridazine, thus making it possible to apply the bifidum-containing drugs as basic agents in the treatment of ReA.